SARS-CoV-2 Variants in COVID-19 Disease: A Focus on Disease Severity and Vaccine Immunity in Patients Admitted to the Emergency Department
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Viral RNA Extraction and RT-PCR Reaction
2.3. Whole Genome Sequencing for VOCs Identification
2.4. Statistical Analysis
3. Results
3.1. Study Population
3.2. SARSCoV-2 Identification and Sample Sequencing
4. Discussion
Limitation of the Study
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tao, K.; Tzou, P.L.; Nouhin, J.; Gupta, R.K.; de Oliveira, T.; Kosakovsky Pond, S.L.; Fera, D.; Shafer, R.W. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 2021, 22, 757–773. [Google Scholar] [CrossRef] [PubMed]
- WHO. SARS-CoV-2 Variants of Concern and Variants of Interest; World Health Organization: Geneva, Switzerland, 2021; Available online: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed on 1 March 2021).
- CDC. SARS-CoV-2 Variant Classifications and Definitions; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2021. Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html (accessed on 1 March 2021).
- The COVID-19 Genomics UK (COG-UK) Consortium. An integrated national scale SARS-CoV-2 genomic surveillance network. Lancet Microbe 2020, 1, e99–e100. [Google Scholar] [CrossRef] [PubMed]
- Rambaut, A.; Holmes, E.C.; O’Toole, A.; Hill, V.; McCrone, J.T.; Ruis, C.; du Plessis, L.; Pybus, O.G. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 2020, 5, 1403–1407. [Google Scholar] [CrossRef] [PubMed]
- Fontanet, A.; Autran, B.; Lina, B.; Kieny, M.P.; Karim, S.S.A.; Sridhar, D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet 2021, 397, 952–954. [Google Scholar] [CrossRef] [PubMed]
- Grubaugh, N.D.; Gangavarapu, K.; Quick, J.; Matteson, N.L.; De Jesus, J.G.; Main, B.G.; Tan, M.L.; Paul, L.M.; Brackney, D.E.; Grewal, S.; et al. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 2019, 20, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Otto, S.P.; Day, T.; Arino, J.; Colijn, C.; Dushoff, J.; Li, M.; Mechai, S.; Van Domselaar, G.; Wu, J.; Earn, D.J.D.; et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr. Biol. 2021, 31, R918–R929. [Google Scholar] [CrossRef]
- He, X.; Hong, W.; Pan, X.; Lu, G.; Wei, X. SARS-CoV-2 Omicron variant: Characteristics and prevention. Med. Commun. 2021, 2, 838–845. [Google Scholar] [CrossRef]
- Daria, S.; Bhuiyan, M.A.; Islam, M.R. Detection of highly muted coronavirus variant Omicron (B.1.1.529) is triggering the alarm for South Asian countries: Associated risk factors and preventive actions. J. Med. Virol. 2022, 94, 1267–1268. [Google Scholar] [CrossRef]
- Saxena, S.K.; Kumar, S.; Ansari, S.; Paweska, J.T.; Maurya, V.K.; Tripathi, A.K.; Abdel-Moneim, A.S. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern and its global perspective. J. Med. Virol. 2022, 94, 1738–1744. [Google Scholar] [CrossRef]
- Patalon, T.; Gazit, S.; Pitzer, V.E.; Prunas, O.; Warren, J.L.; Weinberger, D.M. Odds of testing positive for SARS-CoV-2 following receipt of 3 vs. 2 doses of the BNT162b2 mRNA vaccine. JAMA Intern. Med. 2022, 182, 179–184. [Google Scholar] [CrossRef]
- Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N. Engl. J. Med. 2021, 385, 1393–1400. [Google Scholar] [CrossRef]
- Andrews, N.; Stowe, J.; Kirsebom, F.; Gower, C.; Ramsay, M.; Bernal, J.L. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against COVID-19 related symptoms in England: Test negative case-control study. Nat. Med. 2022, 28, 831–837. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. CDC Expands COVID-19 Booster Recommendations. 2021. Available online: https://www.cdc.gov/media/releases/2021/s1129-booster-recommendations.html (accessed on 2 December 2021).
- Wichaidit, M.; Nopsopon, T.; Sunan, K.; Phutrakool, P.; Ruchikachorn, P.; Wanvarie, D.; Pratanwanich, P.N.; Cheewaruangroj, N.; Punyabukkana, P.; Pongpirul, K. Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: A prospective cohort study. Lancet Reg. Health Southeast Asia 2023, 8, 100106. [Google Scholar] [CrossRef]
- Babouee, F.B.; Güsewell, S.; Egger, T.; Leal, O.; Brucher, A.; Lemmenmeier, E.; Meier Kleeb, D.; Möller, J.C.; Rieder, P.; Rütti, M.; et al. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study. PLoS Med. 2022, 19, e1004125. [Google Scholar]
- Kshirsagar, M.; Nasir, M.; Mukherjee, S.; Becker, N.; Dodhia, R.; Weeks, W.B.; Ferres, J.L.; Richardson, B. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data. JMIR Public Health Surveill. 2022, 8, e38898. [Google Scholar] [CrossRef]
- Stalman, E.W.; Wieske, L.; van Dam, K.P.J.; Kummer, L.Y.; van Kempen, Z.L.E.; Killestein, J.; Volkers, A.G.; Tas, S.W.; Boekel, L.; Wolbink, G.J.; et al. T2B immunity against SARS-CoV-2 study group. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Ann. Rheum. Dis. 2022, 81, 1757–1766. [Google Scholar]
- Bajči, M.P.; Lendak, D.F.; Ristić, M.; Drljača, M.M.; Brkić, S.; Turkulov, V.; Petrović, V. COVID-19 Breakthrough Infections among Patients Aged ≥65 Years in Serbia: Morbidity and Mortality Overview. Vaccines 2022, 10, 1818. [Google Scholar] [CrossRef]
- Ward, H.; Whitaker, M.; Flower, B.; Tang, S.N.; Atchison, C.; Darzi, A.; Donnelly, C.A.; Cann, A.; Diggle, P.J.; Ashby, D.; et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 2022, 13, 907. [Google Scholar] [CrossRef]
- Guven, D.C.; Sahin, T.K.; Kilickap, S.; Uckun, F.M. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. Front. Oncol. 2021, 11, 759108. [Google Scholar] [CrossRef]
- Sakuraba, A.; Luna, A.; Micic, D. A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients. Viruses 2022, 14, 1822. [Google Scholar] [CrossRef]
- Pascarella, S.; Ciccozzi, M.; Bianchi, M.; Benvenuto, D.; Cauda, R.; Cassone, A. The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern. J. Infect. 2022, 84, e62–e63. [Google Scholar] [CrossRef] [PubMed]
Vaccination Status | Discharge Home n.(%) | Hospital Admission n.(%) | Intensive Care Unit Admission n. (%) | 30-Day Mortality n. (%) |
---|---|---|---|---|
No dose | 5 (36) | 13 (48) | 2 * (100) | 2 * (100) |
One dose | 1 (7) | 1 (4) | 0 | 0 |
Two doses or one dose plus infection | 1 (7) | 3 (11) | 0 | 0 |
Three doses | 7 (50) | 10 (37) | 0 | 0 |
Total | 14 (100) | 27 (100) | 2 (100) | 2 (100) |
Vaccination Status | Patients Discharged Home n. (%) | Patients with Comorbidities (n., %) |
No dose | 5 (36) | Diabetes (1, 20) |
One dose | 1 (7) | None |
Two doses or one dose plus infection | 1 (7) | Hypertension (1, 100) |
Three doses | 7 (50) | -Diabetes + Hypertension (1, 14) -Prior cerebral hemorrhage resulting in hemiparesis (1, 14) |
Total | 14 (100) | 4 (28) |
Vaccination status | Patients admitted to hospital n. (%) | Patients with comorbidities (n., %) |
No dose | 13 | -Neoplastic disease (1, 8) -Diabetes + Hypertension (3, 23) -Diabetes + Heart and Renal Failure (1, 8) |
One dose | 1 | Heart Failure (1, 100) |
Two doses or one dose plus infection | 3 | -Neoplastic disease (1, 33) -Diabetes (1, 33) -Hypertension (1, 33) |
3 dose | 10 | -Neoplastic disease (3, 30) -Diabetes + Hypertension + COPD (1, 10) -Cardiomiopathy + Hypertension (1, 10) -COPD (2, 20) |
Total | 27 (100) | 7 (70) |
Vaccination status | Patients admitted to Intensive Care Unit n. (%) | Patients with comorbidities (n., %) |
None | 2 (100) | -Heart Failure (1, 50) -Diabetes + Heart and Renal Failure (1, 50) |
Total | 2 (100) * | 2 (100) * |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fogolari, M.; Francesconi, M.; De Florio, L.; Giovanetti, M.; Veralli, R.; De Flora, C.; Maruotti, A.; Scarpa, F.; Spoto, S.; Sambuco, F.; et al. SARS-CoV-2 Variants in COVID-19 Disease: A Focus on Disease Severity and Vaccine Immunity in Patients Admitted to the Emergency Department. J. Pers. Med. 2022, 12, 2001. https://doi.org/10.3390/jpm12122001
Fogolari M, Francesconi M, De Florio L, Giovanetti M, Veralli R, De Flora C, Maruotti A, Scarpa F, Spoto S, Sambuco F, et al. SARS-CoV-2 Variants in COVID-19 Disease: A Focus on Disease Severity and Vaccine Immunity in Patients Admitted to the Emergency Department. Journal of Personalized Medicine. 2022; 12(12):2001. https://doi.org/10.3390/jpm12122001
Chicago/Turabian StyleFogolari, Marta, Maria Francesconi, Lucia De Florio, Marta Giovanetti, Roberta Veralli, Cecilia De Flora, Antonello Maruotti, Fabio Scarpa, Silvia Spoto, Federica Sambuco, and et al. 2022. "SARS-CoV-2 Variants in COVID-19 Disease: A Focus on Disease Severity and Vaccine Immunity in Patients Admitted to the Emergency Department" Journal of Personalized Medicine 12, no. 12: 2001. https://doi.org/10.3390/jpm12122001